Filing Details
- Accession Number:
- 0001179110-20-012194
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-22 18:45:51
- Reporting Period:
- 2020-12-18
- Accepted Time:
- 2020-12-22 18:45:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 861838 | Idera Pharmaceuticals Inc. | IDRA | Biological Products, (No Disgnostic Substances) (2836) | 043072298 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1187159 | Vincent Milano | C/O Idera Pharmaceuticals, Inc. 505 Eagleview Blvd., Suite 212 Exton PA 19341 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-12-18 | 128,170 | $0.00 | 251,730 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2020-12-22 | 37,169 | $4.32 | 214,561 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Footnotes
- As previously disclosed in the Company's securities filings, on December 18, 2020 (the "Grant Date"), Reporting Person received an award of restricted stock units ("RSUs") in lieu of salary pursuant to a January 10, 2020 amendment to Reporting Person's employment agreement, granted consistent with Issuer's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock of the Issuer. The RSUs were fully vested on the Grant Date.
- The sales represent the sale of shares necessary to meet tax withholding obligations in connection with the settlement of the RSUs, and were effected pursuant to a Rule 10b5-1 trading plan adopted between the Company and the Reporting Person on September 30, 2020. The sales do not represent a discretionary trade by the Reporting Person.
- The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.54 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Of the reported securities beneficially owned, 62,313 shares are represented by unvested RSUs.
Billionaire Hedge Funds
